Free shipping on all orders over $ 500

Aprepitant

Cat. No. M1650
Aprepitant Structure
Synonym:

MK-0869, L-754030, Emend

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL USD 70  USD70 In stock
5mg USD 55  USD55 In stock
10mg USD 80  USD80 In stock
50mg USD 300  USD300 In stock
100mg USD 440  USD440 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Aprepitant (Emend) is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor.Aprepitant has been shown to inhibit both the acute and delayed emesis induced by cytotoxic chemotherapeutic drugs by blocking substance P landing on receptors in the brains neurons.

Protocol (for reference only)
Cell Experiment
Cell lines human CAPAN pancreas, HEp-2 larynx, gastric 23132-87 and SW-403 colon carcinoma cells
Preparation method Proliferation assays.
Cell proliferation was evaluated using the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS), according to the manufacturer’s instructions (CellTiter 96 Aqueous One Solution Cell Proliferation Assay). Cell numbers were quantified using a Coulter counter. Cells were cultured in 96-well plates: each well contained 104 cells in a total volume of 100 µl. Each assay included one plate The plate included blank wells (0 cells/0.1 ml), control wells (104 cells /0.1 ml), control wells with acetonitrylo, control wells treated with aprepitant and control wells treated with the most effective SP concentration and aprepitant. The plates were inoculated with aprepitant (5–70 µM for tumor cell lines) and were incubated for the first doubling time specific for each tumor cell line. The plates were also inoculated the most mitogenic exogenous SP nM concentration with the fifty-percent inhibition concentration (IC50) of aprepitant µM concentration approximately and without aprepitant for their first doubling times respectively. For the proliferation assay, 20 µl of the MTS reagent was added to each well 90 min before reading the samples on a multiscanner microplate reader (TECAN Spectra classic, Barcelona, Spain) at 492 nm. The quantity of product, as measured by optical density, is directly proportional to the number of living cells.
Concentrations 5-70 µM
Incubation time 2 days
Animal Experiment
Animal models acute cisplatin-induced emesis in ferrets
Formulation Methocel or PEG 300
Dosages 0.3, 1, 3mg/kg
Administration p.o. or i.v.
Chemical Information
Molecular Weight 534.43
Formula C23H21F7N4O3
CAS Number 170729-80-3
Solubility (25°C) DMSO 90 mg/mL
Storage 2-8°C, protect from light
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Albany et al. J Clin Oncol. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.

[2] Stiff et al. Biol Blood Marrow Transplant. Prevention of Nausea and Vomiting Associated with Stem Cell Transplantation: Results of a Prospective, Randomized Trial of Aprepitant used with Highly Emetogenic Preparative Regimens.

[3] Bergese et al. Trials. Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol for a randomized controlled trial.

[4] Green et al. Br J Anaesth. Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant and transdermal scopolamine for prevention of postoperative nausea and vomiting.

[5] Longo et al. Int J Clin Pract. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.

[6] Munoz M, et al. Invest New Drugs. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.

[7] Tattersall FD, et al. Neuropharmacology. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.

Related Neurokinin Receptor Products
Spantide II

Spantide II, an undecapeptide substance P (SP) analog, is a potent neurokinin-1 receptor (NK-1R) antagonist.

Substance P (7-11)

Substance P (7-11) is a C-terminal fragment of Substance P which can cause an increase in the intracellular calcium concentration.

[Sar9, Met(O2)11]-Substance P TFA

[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK1 receptor selective agonist.

[bAla8]-Neurokinin A(4-10)

[bAla8]-Neurokinin A(4-10) is a neurokinin 2 (NK2) receptor agonist.

[Sar9, Met(O2)11]-Substance P

[Sar9,Met(O2)11]-Substance P is a tachykinin NK1 receptor selective agonist.

  Catalog
Abmole Inhibitor Catalog




Keywords: Aprepitant, MK-0869, L-754030, Emend supplier, Neurokinin Receptor, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.